A label revision for Dapagliflozin (Farxiga) was made effective on 2026-05-11 by the FDA. The update specifically addresses the "INDICATIONS AND USAGE" section, adding a new indication for reducing the risk of hospitalization for heart failure.
Background
The updated label for Dapagliflozin (Farxiga) now includes a significant indication: to reduce the risk of hospitalization for heart failure. This specific benefit is targeted towards adults who have type 2 diabetes mellitus. Furthermore, this indication applies to individuals within this population who have either established cardiovascular disease or possess multiple cardiovascular risk factors. This clarifies and formalizes the drug's role in addressing a critical cardiovascular complication often associated with type 2 diabetes, highlighting its utility beyond its primary role in glycemic control. The expanded indication reflects a deeper understanding of the drug's pleiotropic effects on cardiovascular health.
What this means
This FDA label revision for Dapagliflozin (Farxiga) provides clinicians with an important expanded therapeutic option. It explicitly recognizes the drug's ability to reduce the risk of hospitalization for heart failure in a well-defined patient group: adults living with type 2 diabetes mellitus who are already facing cardiovascular challenges, either through established disease or multiple risk factors. This update underscores the growing understanding of Dapagliflozin's benefits beyond glycemic control, positioning it as a valuable tool in comprehensive cardiovascular risk management strategies for these vulnerable patients. The formal inclusion of this indication on the label supports evidence-based prescribing decisions aimed at improving patient outcomes related to heart failure and may influence treatment guidelines for individuals with type 2 diabetes and cardiovascular risk.
Source
The information regarding this label revision was obtained from the FDA, as detailed in a document available on the DailyMed website. The update to the "INDICATIONS AND USAGE" section of the Dapagliflozin label was effective on 2026-05-11 and is accessible via dailymed.nlm.nih.gov.